Galmed Pharmaceuticals Ltd. Form 6-K
July 19, 2018
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of July 2018
001-36345
(Commission File Number)
GALMED PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in its charter)
(
46 TEL 11 G
16 Tiomkin St.
Tel Aviv 6578317, Israel

(Address of principal executive offices)

Edgar Filing: Galmed Pharmaceuticals Ltd. - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F x Form 40-F "
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7):

Edgar Filing: Galmed Pharmaceuticals Ltd. - Form 6-K

Galmed Pharmaceuticals Ltd. announces that it will hold an Annual General Meeting of Shareholders on Thursday, August 30, 2018 at 5:00 p.m. (Israel time) at the offices of the Company at 16 Tiomkin St., Tel Aviv, Israel. A copy of the Notice of the Annual General Meeting of Shareholders and Proxy Statement and the Proxy Card are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.

The information contained this Form 6-K is incorporated by reference into the Company's Registration Statement on Form S-8 filed with the SEC on August 11, 2015 (Registration No. 333-206292) and its Registration Statement on Form F-3 filed with the SEC on March 26, 2018 (Registration No. 333-223923).

Edgar Filing: Galmed Pharmaceuticals Ltd. - Form 6-K

Exhibit Index

Exhibit No. Description

- 99.1 Notice of the Annual General Meeting of Shareholders and Proxy Statement
- 99.2 Proxy Card

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GALMED PHARMACEUTICALS LTD.

Date: July 19, 2018 By:/s/ Allen Baharaff Allen Baharaff

President and Chief Executive Officer